Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-WEEK RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLLED, MULTICENTRE CLINICAL TRIAL, TO ASSESS THE EFFICACY AND SAFETY OF 200 μg OF THE ANTICHOLINERGIC LAS 34273 COMPARED TO PLACEBO, BOTH ADMINISTERED ONCE DAILY BY INHALATION, IN THE MAINTENANCE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE, STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Trial Profile

A 52-WEEK RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLLED, MULTICENTRE CLINICAL TRIAL, TO ASSESS THE EFFICACY AND SAFETY OF 200 μg OF THE ANTICHOLINERGIC LAS 34273 COMPARED TO PLACEBO, BOTH ADMINISTERED ONCE DAILY BY INHALATION, IN THE MAINTENANCE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE, STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aclidinium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ACCLAIM-I; ACCLAIM/COPD-I
  • Sponsors Almirall S.A.
  • Most Recent Events

    • 03 Nov 2012 Planned number of patients 1260 added as reported by European Clinical Trials Database.
    • 12 Sep 2009 Results presented at the 19th Annual Congress of the European Respiratory Society.
    • 12 Sep 2009 Primary endpoint 'Forced expiratory volume in 1 second' has been met according to results presented at the 19th Annual Congress of the European Respiratory Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top